PVR and glioblastoma: We initially considered that CD155 may be expressed in neurogenic sarcomas, such as MPNST, since the upregulation of CD155 expression in previous studies was mainly observed in neuroectodermal malignancies (e.g. glioblastoma, medulloblastoma or neuroblastoma) (27,28,29).